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Abstract 1 
Background: Recent data have raised concerns about the risk/benefit ratio of thrombolysis in 2 
non-high risk pulmonary embolism patients due to increased serious bleeding events. Whether 3 
cardiac biomarkers could be of help for bleeding risk stratification in this setting remains 4 
elusive. 5 
Objectives: To determine the prognostic accuracy of hs-cTnT, NT-proBNP, RIETE and PESI 6 
score for the occurrence of clinically relevant bleeding (CRB) in elderly patients under 7 
conventional anticoagulation therapy for non-massive pulmonary embolism (NMPE). 8 
Methods: We evaluated 230 elderly patients with available blood sample taken within one 9 
day from diagnosis. The primary study endpoint was CRB at 1, 3 and 24 months. Prognostic 10 
accuracies and associations were determined using C-statistics and subhazard ratios (SHR), 11 
respectively.  12 
Results: hs-cTnT displayed the highest discriminatory power at 1 month (C-statistics: 0.77, 13 
95% CI: 0.68–0.88) which remained stable over time. Although C-statistics comparison 14 
indicated that hs-cTnT was not statistically superior to RIETE score (0.77 vs 0.67, p=0.11), 15 
adding hs-cTnT to RIETE score significantly improved the C-statistics from 0.67 to 0.78 16 
(p=0.02). SHRs indicated that for each hs-cTnT log-unit increase, there was a 58% increase in 17 
the risk of CRB independently of the RIETE score (adjusted SHR: 1.58, 95% CI: 1.31-1.92). 18 
At the pre-specified cut-off of 14 ng/l, the negative predictive value of hs-cTnT was 96.9% 19 
(95% CI: 91.4-99.0) and 94.9 (95%CI: 88.6-97.8) at 1 and 3 months, respectively.  20 
Conclusion: In elderly, hs-cTnT provides incremental prognostic information over the RIETE 21 
score and could represent a valuable tool to identify NMPE patients at low risk of bleeding.  22 
 23 
Keywords:  Natriuretic Peptide, Brain ; Troponin T ; Pulmonary Embolism ; Hemorrhage ; 24 
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Abbreviations list 1 
CRB : clinically relevant bleeding 2 
NMPE : non-massive pulmonary embolism 3 
PE : pulmonary embolism 4 
SHR : subhazard ratios 5 
 6 
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Introduction 1 
Risk stratification in hemodynamically stable patients with pulmonary embolism (PE) has 2 
gained considerable interest as being susceptible to discriminate between non-massive PE 3 
patients at low-risk or those at intermediate risk of complications, which could respectively be 4 
either eligible for an outpatient treatment or susceptible to benefit from thrombolysis on top of 5 
conventional anticoagulation therapy (1–4). Currently, the identification of low-risk patients 6 
mostly rely on the pulmonary embolism severity index (PESI) score known to be effective in 7 
safely identifying such patients that could possibly be treated in an ambulatory fashion 8 
(1,4,5). Cardiac biomarkers, such as B-type natriuretic peptides (BNP and NT-proBNP) and 9 
cardiac troponin have also shown an interesting potential for rule-out purposes given their 10 
negative predictive values above 95% in predicting PE-related complications (6–12), and their 11 
ability to provide incremental prognostic information to PESI score in elderly patients (11). 12 
On the other hand, the optimal identification and management of intermediate risk patient is 13 
still unclear. Knowing whether radiological or biochemical features of right ventricular 14 
dysfunction/dilatation should be used for such purpose is still elusive. Furthermore, current 15 
evidences provided by the Pulmonary Embolism Thrombolysis (PEITHO) randomized-16 
controlled study do not support the need of a more aggressive management by fibrinolysis to 17 
improve short or long term outcomes of such patients (13,14). If those results can be 18 
interpreted as the absence of thrombolysis benefit in PE patients at intermediate risk, they 19 
may also emphasize the need of a prompt and accurate major bleeding risk assessment before 20 
fibrinolytic therapy administration.  21 
Because several cardiac biomarkers-oriented clinical trials in PE used composite endpoints 22 
including the occurrence of bleeding complications (6,7,9–11), and because natriuretic 23 
peptides and troponins have been respectively shown to act in vitro and in vivo as 24 
anticoagulant (15–17) and anti-angiogenic factors (18–21), we hypothesized that high-25 
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sensitive cardiac troponin T (hs-cTnT) and NT-proBNP levels upon admission could also 1 
reflect the global endothelial integrity of the vascular bed, and thereby could predict the 2 
patient propensity of bleeding while under anticoagulation therapy. Therefore, we challenged 3 
the prognostic accuracies of hs-cTnT and NT-proBNP, alone and in combination, to predict 4 
hemorrhagic complications prediction, and compared them to the RIETE score which is 5 
dedicated to assess the hemorrhagic risk in PE patients under anticoagulation (22,23). 6 
 7 
Methods 8 
Patient population and study design 9 
The present study is an ancillary study of a swiss prospective cohort study (SWITCO65+) 10 
which involved university as well as high-volume non-university hospitals. SWITCO65+ 11 
aimed at assessing long-term outcomes of patients aged 65 or older with a diagnosis of deep 12 
vein thrombosis (DVT) or PE (5,11,12). The study protocol was approved by the research 13 
ethics committee of each institution, and all patients provided written informed consent.  14 
A total of 695 patients with acute PE diagnosed from September 2009 to March 2012 were 15 
considered for this study. PE diagnosis was retained after documentation of a DVT with 16 
compression ultrasonography or angiography or when diagnostic imaging were either positive 17 
for PE (pulmonary angiography or spiral CT) or indicated PE with a high probability 18 
(ventilation perfusion scintigraphy) (5,11,12). Briefly, exclusion criteria included thrombosis 19 
at a site other than lower extremity or thrombosis related to catheter insertion, inadequate 20 
fluency in German or French, conditions making follow-up unlikely (i.e. terminal illness) or 21 
informed consent unavailable (i.e. severe dementia) and previous enrolment in the cohort.  22 
For the present study, 10 patients with massive PE as defined with a systolic blood pressure ≤ 23 
90 mmHg (1), as well as 8 patients not allowing use of their personal data or withdrawing 24 
Accepted author’s manuscript. Published in final edited form as: Thrombosis Research. 2020; 
185: 5-12. Publisher DOI: https://doi.org/10.1016/j.thromres.2019.11.006 
6 
 
consent within one day from inclusion, and 450 patients for which blood samples were 1 
obtained later than one day after diagnosis were excluded. In total, 230 patients were available 2 
for the analysis. Baseline demographic characteristics, clinical data and clinical scores (PESI 3 
(24) and RIETE scores) were prospectively collected by medical records review performed by 4 
trained research nurses.  5 
Patients' follow-up 6 
Follow-up was obtained for all patients at 1, 3 and 24 months months after enrolment. Patients 7 
as well as physicians in charge were told to refer to the investigators whenever recurrent 8 
respiratory or lower extremity symptoms occurred. Telephone interviews and face-to-face 9 
evaluations of all patients were organized at the end of the follow-up period by study 10 
coordinators who remained blinded to the results of analyses (25). All health-related events 11 
were reported by patients after hospital discharge (readmission to the hospital, any medical 12 
appointment, treatment modification, medical investigation and/or hemorrhagic 13 
complication). Review of medical files and contact with the family doctor were performed in 14 
case of suspected clinical event. 15 
Definition of endpoints 16 
The predetermined primary endpoint of this study consisted in clinically relevant bleedings  17 
(i.e. combination of clinically relevant non-major bleeding as well as major bleeding). 18 
Clinically relevant nonmajor bleeding episode was defined as bleeding not meeting the 19 
definition of major bleeding, but requiring physician consultation or evaluation in the 20 
emergency department (26).  21 
The secondary endpoint consisted in major bleeding defined as: i) fatal bleeding, and/or ii) 22 
symptomatic bleeding at a critical site (intracranial, intraspinal, intraocular, retroperitoneal, 23 
intra-articular, pericardial or intramuscular with compartment syndrome), and/or iii) overt 24 
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bleeding with a reduction in haemoglobin levels of ≥20 g/L or leading to transfusion of at 1 
least two units of packed red blood cells (27).  2 
Primary and secondary endpoints were adjudicated upon the consensus of a committee that 3 
was blinded to biochemical results.  4 
Sample Collection 5 
Blood collection and sample processing details were described elsewhere (28). 6 
Biochemical Analyses 7 
Blood samples were analysed to the University Hospitals of Geneva so as to minimize 8 
analytical bias. NT-proBNP and hs-cTnT were measured by electrochemiluminescence 9 
methods on routine autoanalysers (Elecsys™, Roche, Switzerland). We used a cut-off of 14 10 
ng/l for hs-cTnT and 300 pg/ml for NT-proBNP. Details for justification of these cut-offs 11 
were described elsewhere (7,11,12,28,29). 12 
RIETE score assessment 13 
The RIETE score allows the determination of major bleeding risk in patients undergoing 14 
anticoagulation treatment for pulmonary embolism (22,23). This score is computed for each 15 
patient according to the presence of six clinical features, including anamnesis of recent 16 
bleeding (< 2 weeks), creatinine value above 106 µmol/L, presence of anemia (Hb <12 g/dL 17 
for women, Hb <13 g/dL for men), presence of malignancy, clinically overt PE, and age >75 18 
years old (22,23). As shown in Table 1, each of these items has a specific weighting which is 19 
summed together to generate a total score with the following risk classes: 0 = low risk, 1-4 = 20 
intermediate risk, above 4 = high risk (22,23). 21 
Table 1. RIETE bleeding risk score and risk classes 22 
Items Points 
Recent major bleeding 2 
Creatinine levels >109 µmol/l 1.5 
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Anemia 1.5 
Cancer 1 
Clinically overt PE 1 
Age >75 years 1 
  
Incident risk of major bleeding per risk class Corresponding cumulated points 
Low risk: 0.3% (95% CI: 0.1-0.6%) 
Intermediate Risk: 2.6% (95% CI: 2.3-2.6%) 
0 
1-4 
High risk: 7.3% (95% CI: 5.6-9.3%) > 4 
  
Adapted from (22,23)  
 1 
Statistical analysis 2 
A Chi-squared test or a non-parametric Wilcoxon rank-sum test were used as appropriate to 3 
compare patients baseline characteristics with and without clinically relevant bleeding. The 4 
Kaplan-Meier technique and the log-rank test were used to estimate and compare the 5 
cumulative incidence of outcomes for categories of biomarker levels. For hs-cTNT and NT-6 
proBNP, we used the prospectively defined and validated cut–offs of 14 ng/l and 300 pg/ml, 7 
respectively (11,12). The discriminative ability of the biomarker levels and the clinical scores 8 
for events up to 1, 3 and 24 months was assessed by Harrell’s C concordance statistics, which 9 
is equivalent to the area under the ROC curve (AUC) in the case of binary outcomes. 10 
Associations of biomarker levels and clinical scores with outcomes were assessed using 11 
competing-risk regression accounting for non-bleeding-related death as a competing event, 12 
according to the method of Fine and Gray (29). Results are reported as unadjusted and 13 
adjusted subhazard ratios (SHR) with corresponding 95% CIs and p-values. SHR are adjusted 14 
for the RIETE score (22,23) and periods of anticoagulation during follow-up as a time-15 
varying covariate for both endpoints. The RIETE score was only adjusted for anticoagulation. 16 
Missing values in score items were assumed to be normal. All analyses were done using Stata 17 
15 (Stata Corporation, College Station, Texas, USA). 18 
Results 19 
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Patients’ baseline characteristics 1 
Patients’ demographic characteristics and median biomarker values upon admission are listed 2 
in Table 2. At inclusion, patients with clinical relevant bleeding during follow-up tended to be 3 
older, were more likely to display an altered mental status, to be diabetic, known for 4 
cerebrovascular events, and to have been immobilized during the last three months (Table 2). 5 
Of note, hs-cTnT as well as the RIETE score upon inclusion were significantly higher in 6 
patients that had a clinically relevant bleeding episode than those who did not during follow-7 
up. There were no other significant differences between these two groups of patients (Table 8 
2).  9 
Table 2. Patients baseline characteristics 10 
 All With CR Bleeding Event 
Without CR 
Bleeding Event p-value 
 % (n) or median (IQR) 
% (n) or 
median (IQR) 
% (n) or 
median (IQR) 
 
total N 230 64 166  
Age 75  (69-82) 77.0  (70.3-83.0) 74.0  (69.0-81.0) 0.050 
Female gender 94 (41%) 25 (39%) 69 (42%) 0.729 
DVT (all) 47 (20%) 12 (19%) 35 (21%) 0.694 
Proximal DVT (versus 
distal) 
41 (18%) 10 (16%) 31 (19%) 0.588 
Systolic BP <100 mmHg 4  (2%) 0  (0%) 4  (2%) 0.210 
Heart rate ≥110 beats/min 27 (12%) 4  (6%) 23 (14%) 0.108 
Respiratory rate ≥30/min 9  (4%) 2  (3%) 7  (4%) 0.649 
Oxygen saturation <90% 23 (10%) 3  (5%) 20 (12%) 0.062 
Temperature <36°C 18  (8%) 4  (6%) 14  (8%) 0.577 
Body mass index (kg/m2) 26.6  (23.9-29.8) 26.6  (23.0-29.6) 26.6  (24.2-29.9) 0.609 
Altered mental status 6 (3%) 4  (6%) 2  (1%) 0.031 
Diabetes mellitus 35 (15%) 14 (22%) 21 (13%) 0.081 
Coronary heart disease 41 (18%) 13 (20%) 28 (17%) 0.541 
Heart failure† 23 (10%) 9 (14%) 14  (8%) 0.202 
Arterial hypertension 150 (65%) 40 (63%) 110 (66%) 0.591 
Chronic renal disease†† 39 (17%) 12 (19%) 27 (16%) 0.653 
Chronic lung disease¶ 33 (14%) 11 (17%) 22 (13%) 0.446 
Cerebrovascular disease‡ 20  (9%) 9 (14%) 11  (7%) 0.073 
Smoker (current or past) 116 (50%) 27 (42%) 89 (54%) 0.146 
Current oestrogen therapy 5 (2%) 1  (2%) 4  (2%) 0.689 
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during the last 3 months 
Major surgery during the 
last 3 months 
33 (14%) 10 (16%) 23 (14%) 0.732 
Immobilization during the 
last 3 months§ 
52 (23%) 20 (31%) 32 (19%) 0.052 
Prior VTE 70 (30%) 21 (33%) 49 (30%) 0.627 
Prior DVT 42 (18%) 13 (20%) 29 (17%) 0.617 
Active cancer# 39 (17%) 10 (16%) 29 (17%) 0.738 
Concomitant antiplatelet 
therapy 
        63 (33%)              20 (37%)               43 (31%)         0.496  
hs-cTnT (ng/l) 16.6 (8.2-33.9) 27.5 (12.5-47.2) 14.6 (6.8-28.7) <0.001 
hs -cTnT > 14 pg/ml 132 (57%) 46 (72%) 86 (52%) 0.006 
NT-proBNP (pg/ml) 634.2 (227.2- 
2191.8) 
957.0 (334.1-
2286.3) 
554.7 (186.4-
2134.5) 
0.187 
NT-proBNP > 300 pg/ml 157 (68%) 49 (77%) 108 (65%) 0.093 
PESI score 94.0  (80.0-110.3) 91.5 (79.3-114.0) 95.0 (80.0-109.0) 0.794 
PESI > 85 150 (65%) 41 (64%) 109 (66%) 0.819 
RIETE score 2.0   (2.0-3.5) 2.5   (2.0-3.9) 2.0   (1.0-3.5) 0.029 
RIETE > 4 31 (13%) 13 (20%) 18 (11%) 0.059 
Ratio RVEDD¶¶/LVEDD‡‡ 
> 0.9 
        60 (26%)              19 (30%)                41 (25%)        0.730  
 1 
Data were missing for ratio RVEDD/LVEDD > 0.9 (20%), respiratory rate (17%), oxygen (7%), temperature (2%), estrogen 2 
therapy (0.4%), smoking status (0.4%), and BMI (0.4%). 3 
 4 
†Acute heart failure NYHA class II/IV during the last 3 months, left or right heart failure, known left ventricular ejection 5 
fraction of <40%, known history of systolic or diastolic heart failure, or forward or backward heart failure. 6 
††Chronic glomerulonephritis, cystic kidney disease, diabetic or hypertensive nephropathy, myeloma-related nephropathy, or 7 
chronic interstitial nephritis. 8 
¶Chronic obstructive pulmonary disease, bronchiectasies, cystic fibrosis, lung fibrosis, or active asthma. 9 
‡Transient ischemic attack or history of ischemic or hemorrhagic stroke. 10 
§Fracture or cast of the lower extremity, voyage in sitting position for >6 hours during the last 3 months, or bed rest >72 11 
hours.  12 
#Cancer (solid or hematologic) requiring surgery, palliative care during the last 3 months, radiotherapy, or chemotherapy. 13 
¶¶RVEDD: right ventricular end-diastolic diameter 14 
‡‡LVEDD: left ventricular end-diastolic diameter 15 
 16 
 17 
 18 
Abbreviations: 19 
DVT: deep venous thrombosis 20 
 21 
Incidence of endpoints according to different follow-up period 22 
Clinically relevant bleeding was observed in 8.8% (20/230) of patients up to 1 month, 12.3% 23 
(28/230) up to 3 months and 29.1% (64/230) up to 24 months. 24 
Major bleeding was seen in 6.2% (14/230) of patients up to 1 month, 7.0 % (16/230) up to 3 25 
months and 14.1% (31/230) up to 24 months (Table S1 - supplementary data). 26 
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 1 
Associations of cardiac biomarkers, PESI and RIETE score with 2 
study endpoints 3 
As shown in Table 3 and Fig. 1, with the exception of the PESI score that showed no 4 
discrimination at any time during follow-up, both cardiac biomarkers and the RIETE score 5 
displayed a significant discriminative power for clinically relevant bleeding. hs-cTnT had the 6 
highest prognostic accuracy for the occurrence of clinically relevant bleeding at one month 7 
but was not statistically superior to the RIETE score (respective C-statistics: 0.77 vs 0.67, 8 
p=0.118). When hs-cTnT was added to the RIETE score, the C-statistics increased 9 
significantly from 0.67 (95% CI: 0.55-0.79) to 0.78 (95% CI: 0.67-0.82, p=0.023). On the 10 
other hand, adding the RIETE score to hs-cTnT did not substantially increase the C-statistics 11 
(0.77 to 0.78, p=0.782). Similar trends were observed with major bleeding (Table 4). 12 
Table 3. C-statistics evolution and comparison for biomarkers, RIETE and PESI score 13 
for clinically relevant bleeding 14 
 C-statistics* 
(95% CI) 
p-value  
1 month    
hs-cTnT (ng/l) 0.77 (0.66-0.88)   
NT-proBNP (pg/ml) 0.63 (0.52-0.74)   
PESI score 0.50 (0.36-0.64)   
RIETE score 0.67 (0.55-0.79)   
hs-cTnT (ng/l) added to RIETE score 0.78 (0.67-0.89) 0.023  
RIETE score added to hs-cTnT (ng/l) 0.78 (0.67-0.89) 0.782  
C-statistics comparison   
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.009 
hs-cTNT (ng/ml) vs RIETE score  0.118  
NT-proBNP (pg/ml) vs RIETE score  0.424 
3 months    
hs-cTnT (ng/l) 0.75 (0.66-0.84)   
NT-proBNP (pg/ml) 0.63 (0.53-0.72)   
PESI score 0.51 (0.40-0.63)   
RIETE score 0.66 (0.55-0.76)   
hs-cTnT (ng/l) added to RIETE score 0.75 (0.65-0.84) 0.017  
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RIETE score added to hs-cTnT (ng/l) 0.75 (0.65-0.84) 0.923  
C-statistics comparison    
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.013  
hs-cTNT (ng/ml) vs RIETE score  0.085  
NT-proBNP (pg/ml) vs RIETE score  0.550  
24 months    
hs-cTnT (ng/l) 0.67 (0.61-0.74)   
NT-proBNP (pg/ml) 0.58 (0.52-0.65)   
PESI score 0.53 (0.46-0.61)   
RIETE score 0.61 (0.54-0.68)   
hs-cTnT (ng/l) added to RIETE score 0.67 (0.60-0.74) 0.034  
RIETE score added to hs-cTnT (ng/l) 0.67 (0.60-0.74) 0.667  
C-statistics comparison    
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.005  
hs-cTNT (ng/ml) vs RIETE score  0.104  
NT-proBNP (pg/ml) vs RIETE score  0.510  
*all variables are used continuous 1 
Table 4. C-statistics evolution and comparison for biomarkers, RIETE and PESI score 2 
for major bleeding 3 
 C-statistics* 
(95% CI) 
p-value  
1 month    
hs-cTnT (ng/l) 0.73 (0.59-0.88)   
NT-proBNP (pg/ml) 0.63 (0.51-0.76)   
PESI score 0.49 (0.35-0.64)   
RIETE score 0.68 (0.54-0.82)   
hs-cTnT (ng/l) added to RIETE score 0.74 (0.60-0.88) 0.069  
RIETE score added to hs-cTnT (ng/l) 0.74 (0.60-0.88) 0.870  
C-statistics comparison   
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.045 
hs-cTNT (ng/ml) vs RIETE score  0.441  
NT-proBNP (pg/ml) vs RIETE score  0.527 
3 months    
hs-cTnT (ng/l) 0.75 (0.62-0.88)   
NT-proBNP (pg/ml) 0.67 (0.55-0.78)   
PESI score 0.55 (0.40-0.69)   
RIETE score 0.70 (0.57-0.83)   
hs-cTnT (ng/l) added to RIETE score 0.76 (0.63-0.88) 0.043  
RIETE score added to hs-cTnT (ng/l) 0.76 (0.63-0.88) 0.925  
C-statistics comparison    
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.054  
hs-cTNT (ng/ml) vs RIETE score  0.418  
NT-proBNP (pg/ml) vs RIETE score  0.578  
24 months    
hs-cTnT (ng/l) 0.65 (0.54-0.75)   
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NT-proBNP (pg/ml) 0.62 (0.53-0.71)   
PESI score 0.53 (0.43-0.63)   
RIETE score 0.66 (0.56-0.76)   
hs-cTnT (ng/l) added to RIETE score 0.67 (0.57-0.77) 0.461  
RIETE score added to hs-cTnT (ng/l) 0.67 (0.57-0.77) 0.555  
C-statistics comparison    
hs-cTnT (ng/l) vs NT-proBNP (pg/ml)  0.497  
hs-cTNT (ng/ml) vs RIETE score  0.840  
NT-proBNP (pg/ml) vs RIETE score  0.457  
*all variables are used continuous 1 
 2 
On the other hand, the prognostic accuracy of NT-proBNP was substantially lower for the 3 
primary endpoint with C-statistics value of 0.63 (95% CI: 0.52 – 0.74), 0.63 (95% CI: 0.53 – 4 
0.72) and 0.58 (95% CI: 0.52 – 0.65) at 1, 3, and 24 months, respectively. The PESI score did 5 
not predict the primary outcome with significant accuracy at any time of the follow-up (Table 6 
3 and Fig. 1). 7 
 8 
Fig 1. ROC curve analysis for clinically relevant bleeding at 1 month. ROC curves for hs-9 
cTnT, NT-proBNP, RIETE and PESI score are shown. 10 
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 12 
Corroborating these results, competing-risks regression analyses indicated that values of hs-13 
cTnT above 14 ng/l were significantly associated with clinically relevant bleeding at 24 14 
months before (SHR 2.25, 95% CI: 1.32 – 3.86) and after (SHR 1.87, 95% CI: 1.05 – 3.34) 15 
Accepted author’s manuscript. Published in final edited form as: Thrombosis Research. 2020; 
185: 5-12. Publisher DOI: https://doi.org/10.1016/j.thromres.2019.11.006 
14 
 
adjustment for the RIETE score (Table 5). When used as a continuous variable, hs-cTnT was 1 
significantly associated with clinically relevant bleeding over the 24 months follow-up period 2 
after adjustment for RIETE score with SHR (95% CI) ranging from 1.58 (1.31 – 1.92) up to 1 3 
month to l.31 (1.10 – 1.55) up to 24 months per log-unit increase. Regarding NT-proBNP 4 
values above 300 pg/ml, significant associations with the primary endpoint were observed up 5 
to 3 months (SHR: 4.09, 95% CI: 1.23 – 13.59) and 24 months (SHR: 1.77, 95% CI: 1.01 – 6 
3.10) before adjustment. However, after adjustment, associations were not significant 7 
anymore. Unlike hs-cTnT, NT-proBNP was not significantly associated with clinically 8 
relevant bleeding at any time after adjustment for RIETE score when used as a continuous 9 
variable. PESI score was not associated with the primary endpoint at any time while RIETE 10 
score showed an increased SHR ranging between 1.58 (95% CI: 1.16 – 2.16) up to 1 month 11 
and 1.30 (95% CI: 1.07 – 1.57) up to 24 months (Table 5). Analysis results for major bleeding 12 
showed similar trends (Table S2 - supplementary data). 13 
Table 5. Association of biomarkers, PESI and RIETE score with clinically relevant 14 
bleeding. 15 
 Crude SHR (95% CI) p-value 
Adjusted SHR* 
(95% CI) p-value 
1 month     
hs-cTnT >14ng/l 4.43 (1.30 - 15.07) 0.017 3.16 (0.86 - 11.68) 0.084 
hs-cTnT (ng/l)1 1.59 (1.31 - 1.93) <0.001 1.58 (1.31 - 1.92) <0.001 
NT-proBNP >300pg/ml 4.30 (0.99 - 18.69) 0.052 3.00 (0.74 - 12.14) 0.124 
NT-proBNP (pg/ml)1 1.23 (0.95 - 1.60) 0.120 1.06 (0.81 - 1.39) 0.676 
PESI score2 0.99 (0.81 - 1.20) 0.900 0.83 (0.63 - 1.09) 0.182 
RIETE score3 1.58 (1.16 - 2.16) 0.004 1.60 (1.17 - 2.19) 0.004 
3 months     
hs-cTnT >14ng/l 3.70 (1.42 - 9.64) 0.008 2.68 (0.99 - 7.26) 0.053 
hs-cTnT (ng/l)1 1.52 (1.26 - 1.83) <0.001 1.51 (1.26 - 1.82) <0.001 
NT-proBNP >300pg/ml 4.09 (1.23 - 13.59) 0.021 2.95 (0.92 - 9.52) 0.070 
NT-proBNP (pg/ml)1 1.26 (1.01 - 1.57) 0.043 1.10 (0.88 - 1.37) 0.386 
PESI score2 1.02 (0.87 - 1.20) 0.781 0.88 (0.69 - 1.14) 0.335 
RIETE score3 1.55 (1.19 - 2.03) 0.001 1.56 (1.20 - 2.04) 0.001 
24 months     
hs-cTnT >14ng/l 2.25 (1.32 - 3.86) 0.003 1.87 (1.05 - 3.34) 0.034 
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hs-cTnT (ng/l)1 1.34 (1.14 - 1.58) <0.001 1.31 (1.10 - 1.55) 0.002 
NT-proBNP >300pg/ml 1.77 (1.01 - 3.10) 0.046 1.40 (0.77 - 2.54) 0.266 
NT-proBNP (pg/ml)1 1.10 (0.94 - 1.28) 0.228 1.01 (0.87 - 1.19) 0.864 
PESI score2 1.03 (0.92 - 1.14) 0.638 0.95 (0.83 - 1.10) 0.486 
RIETE score3 1.30 (1.07 - 1.57) 0.007 1.32 (1.09 - 1.60) 0.004 
1Biomarkers were log-transformed and used continuous. Effects (SHRs) are expressed per one log-unit increase. 1 
2 Effects (SHRs) are expressed per 10 score points increase. 2 
3 Effects (SHRs) are expressed per score point increase. 3 
*adjusted for RIETE score and periods of anticoagulation as a time-varying covariate. The RIETE score itself 4 
was only adjusted for anticoagulation. 5 
 6 
Kaplan-Meier curves showed that patients with either hs-cTnT or NT-proBNP values above 7 
the pre-specified cut-off had a significantly higher cumulative incidence of clinically relevant 8 
bleeding up to 24 months than patients with values below the cut-off (37% vs 23% for NT-9 
proBNP and 41% vs 20% for hs-cTnT, Fig. 2). Regarding major bleeding, only NT-proBNP 10 
values above the pre-specified cut-off had a significantly higher cumulative incidence of 11 
events compared to values below the cut-off (Fig. S3 - supplementary data). 12 
Fig 2. Cumulative incidence of clinically relevant bleeding by level of hs-cTnT (left 13 
panel) and NT-proBNP (right panel). High versus low levels are based on pre-specified cut-14 
offs (>14 ng/l for hs-cTnT and >300 pg/ml for NT-proBNP). 15 
 16 
Table 6 summarizes specificity, sensitivity, and predictive values for each cardiac biomarker, 17 
PESI and RIETE score regarding clinically relevant bleeding over time. Both hs-cTnT and 18 
NT-proBNP tend to have a higher negative predictive value (NPV) than RIETE score at any 19 
time point considered. At the pre-specified cut-offs for NT-proBNP (300 pg/ml) and hs-cTnT 20 
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(14 ng/L), NPVs were 97.3% (95% CI: 90.5 – 99.2) and 96.9% (95% CI: 91.4 – 99.0), 1 
respectively, up to 1 month and remained over 79.5% (95% CI: 68.8 – 87.1) and 81.6% (95% 2 
CI: 72.8 – 88.1), respectively, during the 24 months follow-up period. RIETE score showed 3 
slightly lower NPV values ranging between 93.5% (95% CI: 89.1 – 96.1) up to 1 month and 4 
74.4% (95% CI: 67.9 – 79.9) up to 24 months. Values for major bleeding showed similar 5 
trends (Table S4 - supplementary data). 6 
Table 6. Evolution of sensitivity, specificity, and predictive values over time with 7 
clinically relevant bleeding. 8 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV1 
(95% CI) 
NPV2 
(95% CI) 
1 month     
hs-cTnT >14ng/l 85.0 (64.0-94.8) 45.2 (38.7-52.0) 12.9 (8.2-19.7) 96.9 (91.4-99.0) 
NT-proBNP >300pg/ml 90.0 (69.9-97.2) 33.8 (27.8-40.4) 11.5 (7.4-17.4) 97.3 (90.5-99.2) 
PESI score > 85 60.0 (38.7-78.1) 34.3 (28.2-40.9) 8.0 (4.6-13.5) 90.0 (81.5-94.8) 
RIETE score > 4 35.0 (18.1-56.7) 88.6 (83.6-92.2) 22.6 (11.4-39.8) 93.5 (89.1-96.1) 
3 months     
hs-cTnT >14ng/l 82.1 (64.4-92.1) 46.0 (39.3-52.9) 17.4 (11.9-24.8) 94.9 (88.6-97.8) 
NT-proBNP >300pg/ml 89.3 (72.8-96.3) 34.7 (28.4-41.4) 15.9 (11.0-22.5) 95.9 (88.6-98.6) 
PESI score > 85 60.7 (42.4-76.4) 34.2 (28.0-40.9) 11.3 (7.2-17.4) 86.3 (77.0-92.1) 
RIETE score > 4 32.1 (17.9-50.7) 89.1 (84.1-92.7) 29.0 (16.1-46.6) 90.5 (85.6-93.8) 
24 months     
hs-cTnT >14ng/l 71.9 (59.9-81.4) 48.2 (40.7-55.7) 34.8 (27.3-43.3) 81.6 (72.8-88.1) 
NT-proBNP >300pg/ml 76.6 (64.9-85.3) 34.9 (28.1-42.5) 31.2 (24.5-38.8) 79.5 (68.8-87.1) 
PESI score > 85 64.1 (51.8-74.7) 34.3 (27.5-41.8) 27.3 (20.8-35.0) 71.3 (60.5-80.0) 
RIETE score > 4 20.3 (12.3-31.7) 89.2 (83.5-93.0) 41.9 (26.4-59.2) 74.4 (67.9-79.9) 
1PPV: positive predictive value 9 
2NPV: negative predictive value 10 
 11 
Discussion 12 
The major finding of this study is that, among both cardiac biomarkers, only hs-cTnT is found 13 
to be an independent predictor of clinically relevant bleeding susceptible to provide 14 
incremental discriminatory power when added to the RIETE score for bleeding risk prediction 15 
in patients anticoagulated for non-high risk PE. On the contrary, hs-cTnT C-statistics is not 16 
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substantially modified after addition of the RIETE score. Even though C-statistics 1 
comparisons between cardiac biomarkers and RIETE score should be considered exploratory 2 
at the present time in PE, these hypothesis-generating results are very similar to what has been 3 
shown in the ARISTOTLE trial for hs-cTnT. Indeed, in this study testing the efficacy and 4 
safety of apixaban in preventing ischemic stroke in more than 14800 patients with atrial 5 
fibrillation (AF), hs-cTnT levels upon admission were found to be significant predictors of 6 
subsequent major bleeding. Moreover, hs-cTnT levels improved the C-statistics of the 7 
esthablished CHA2DS2VASc score (based on the following items: congestive heart failure, 8 
hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient 9 
ischemic attack, vascular disease, 65 to 74 years of age, gender) from 0.591 to 0.629 (p < 10 
0.0001) regarding the risk of major bleeding (30). Although NT-proBNP levels also improved 11 
risk stratification beyond the CHA2DS2VASc risk score, they did not predict subsequent 12 
major bleeding risk (31). If both NT-proBNP and hs-cTnT were shown to be appealing 13 
candidates for risk stratification in PE (6–12), the current results lend weight to the possibility 14 
that hs-cTnT could be the best to capture bleeding propensity upon anticoagulation. In 15 
addition, despite being non-significant, C-statistics differences observed between hs-cTnT and 16 
the RIETE score (∆=0.10) is still of a magnitude order that could be perceived as substantial 17 
(32). Regarding major bleeding assessment, our results show the same trends with a few 18 
exceptions, notably at 24 months of follow-up where RIETE score C-statistics is found to be 19 
superior to hs-cTnT. On the other hand, RIETE score is found to be superior to NT-proBNP at 20 
any time. Of note, PESI score is not shown to be associated with endpoints in this study. This 21 
is not surprising since it has not been developed to predict hemorrhagic complications. 22 
The pathophysiological reasons underlying bleeding risk prediction differences between hs-23 
cTnT and NT-proBNP are still poorly understood and are most likely multifactorial. Indeed, 24 
aside myocardial necrosis and pressure overload, hs-cTn levels are known to be markedly 25 
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influenced by age, myocardial apoptosis and fibrosis, and cardiomyocytes turn-over (33). 1 
Because cTn (mostly cTnI so far) have been shown to act as anti-angiogenic factors 2 
susceptible to disrupt endothelial integrity (18–21), we cannot exclude the fact that hs-cTnT 3 
elevations could also reflect the indivual bleeding propensity. Even without a complete 4 
understanding of the underlying mechanisms associating hs-cTnT with the hemorrhagic risk, 5 
hs-cTnT level below 14 ng/L shows an elevated (96.9%) negative predictive value (NPV) for 6 
a subsequent haemorragic event in PE and this test is available in most routine laboratories. 7 
Whether hs-cTnT could represent an attractive candidate to influence the selection of non-8 
massive PE patients susceptible to benefit from a more aggressive treatment than standard 9 
anticoagulation alone remains an open question. Being at the opposite of most risk 10 
stratification concepts elaborated so far in non-massive PE, such hypothesis warrants further 11 
investigations, especially regarding the definition of an optimal cut-off to be used for such 12 
purpose.  13 
Despite not being optimal for bleeding risk assessment in a rule-in strategy, hs-cTnT values 14 
below 14 ng/l show a higher NPV than RIETE score at any time for clinically relevant 15 
bleeding with value of 96.9% (95% CI: 91.4-99.0) versus 93.5% (95% CI: 89.1-96.1) at 1 16 
month, respectively. In general, hs-cTnT and NT-proBNP NPVs are similar. In contrast, both 17 
hs-cTnT and NT-proBNP display, at the pre-specified cut-off values, positive predictive 18 
values that were not suitable, at least for the elderly, to identify patients with high risk for 19 
bleeding. 20 
This study has several limitations. First, the number of events was limited. Although we 21 
observed significant associations with the primary endpoint when predictors were used 22 
continuous, these associations failed to reach significance when considered as dichotomous in 23 
adjusted analyses. Furthermore, the same trend was observed for the secondary endpoint 24 
indicating that some of the negative findings values reported here are likely to be ascribed to a 25 
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power issue. Therefore, knowing whether the pre-specified cut-off for biomarkers used in 1 
acute coronary syndrome is adequate for bleeding risk stratification has to be answered.  2 
Another limitation resides in the fact that we did not measure the Growth Differentiation 3 
Factor 15 (GDF-15), known to bare strong CV prognostic values in different clinical settings 4 
including PE (34,35), as well as to be a strong predictor of major bleeding in patient 5 
anticoagulated for AF (36). These findings led to the validation of a biomarker-based score 6 
entitled ABC (age, biomarkers, clinical history)-bleeding risk score in AF patients receiving 7 
oral anticoagulant therapy where GDF-15 was one of the most contributing factors (37). 8 
Therefore, the question whether GDF-15 would be more strongly associated with major 9 
bleeding risk in PE than hs-cTnT certainly remains of interest. Another important limitation 10 
of this study resides in the fact that that due to study design, we did not included PE patients 11 
requiring thrombolysis. Therefore, our results cannot be extrapolated to thrombolysed 12 
patients. 13 
Due to a power issue associated with a low number of primary endpoint events in chronic 14 
kidney failure and cancer patients, such confounding factors cannot be excluded as well as the 15 
consequences of different anticoagulant therapy on the occurrence of bleeding. 16 
Finally, the validity of the present results in PE patients that are younger than 65 years-old has 17 
to be established. 18 
 19 
Conclusion 20 
This hypothesis-generating study suggests that hs-cTnT has the highest discriminative 21 
accuracy among tested cardiac biomarkers and the RIETE score for predicting clinically 22 
relevant bleeding. Moreover, given their relatively high negative predictive values for 23 
hemorrhagic complications, knowing whether cardiac biomarkers assessment would improve 24 
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the risk/benefit ratio of thrombolysis in NMPE with radiological signs of right ventricular 1 
dysfunction remains to be demonstrated. 2 
 3 
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